CAR-T immunotherapies may have a new player

(University of California - San Diego) Emerging CAR-T immunotherapies leverage modified versions of patient's T-cells to target and kill cancer cells. In a new study, published June 28 online in Cell Stem Cell, researchers at University of California San Diego School of Medicine and University of Minnesota report that similarly modified natural killer (NK) cells derived from human induced pluripotent stem cells (iPSCs) also displayed heightened activity against a mouse model of ovarian cancer.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news